Plunkett Research Online: Swedish Orphan Biovitrum AB

SWEDISH ORPHAN BIOVITRUM AB (BIOVF:PINX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs i.....



Swedish Orphan Biovitrum AB
Ticker: BIOVF
Exchange: PINX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 46 86972000
Fax: 46 86972330
Address: Tomtebodavagen 23 A
Solna
Stockholm, SE-112 76 Sweden

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
Biopharmaceuticals
Drug Development
Clinical Testing
Contacts Description
Hakan BjorklundChairman of the Board/Director
Staffan SchubergDirector
See More
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs i.....See More See More

Auditor: EY AB,
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Alprolix
Doptelet
Elocta
Gamifant
Kineret
Orfadin
Synagis
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: